Enginprime Medical secures 12 million Series A funding round
Healthcare firm Enginprime Medical secured 12 million dollars in Series A funding led by Qiming Venture Partners on 18 August 2026 for clinical trials
Shanghai and Hangzhou, China - Enginprime Medical, a medical device developer specializing in percutaneous ventricular assist device (pVAD) technology, has successfully closed a $12 million Series A funding round led exclusively by Qiming Venture Partners. The funds will be used to advance the registration of OpusOne™, a next-generation pVAD system, in China, and support regulatory submissions and early-stage clinical development of the platform on a global scale.
Enginprime was founded in 2023 by Voyagers Capital and a team of seasoned engineers, with the mission to create innovative percutaneous ventricular assist systems. The lead product, OpusOne™, boasts higher flow rates from a smaller catheter design, promising to enhance patient eligibility and reduce clinical complications. Zhiyong Liu, Enginprime's CEO, expressed gratitude to Qiming Venture Partners and Voyagers Capital for their strategic backing, stating that the funding represents a significant milestone in scaling a globally competitive pVAD system.
Qiming Venture Partners' Shuo Mao highlighted the unique advantages of the foldable impeller pVAD, emphasizing its potential to broaden patient applicability and reduce clinical complications.
Written by urgent.news from Vietnam Investment Review's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
